生命科學產業十大策略要務（2025 年）

Top 10 Strategic Imperatives in the Life Sciences Industry, 2025

出版日期: 2025年02月19日 | 出版商:

Frost & Sullivan | 英文 34 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

生命科學產業的不斷發展和挑戰要求相關人員保持適應性、創新和競爭力才能取得成功。產業領導者必須每年重新思考他們的策略地位，了解轉型背後的關鍵力量：潛力、挑戰和驅動力。

本報告研究了全球生命科學產業，並提供了市場概況、策略要務和成長機會。

轉型 1：SaaS 的進步將為實驗室提供自適應智慧
轉型二：CDMO 加強新模式能力，數位轉型實現端到端夥伴關係
轉型三：將直接面對消費者 (DTC) 的基因檢測從血統檢測擴展到多致病性行為感染傳染病
轉型四：貿易戰的不確定性擾亂醫藥供應鏈
轉型五：透過分散臨床試驗（DCT）和罕見疾病提高CGT效率
第六次革命：次世代定序（NGS）和液態生物檢體將徹底改變腫瘤診斷
變化七：臨床試驗失敗和市場條件變化阻礙了生物技術創新
轉型 8：ESG舉措成為 CEO 策略重點
轉型 9：現實世界洞察 (RWI) 成為重新思考商業策略的策略指南
革命#10：CRISPR 技術推動生技藥品研發
分析觀點

後續步驟Next steps

簡介目錄

Product Code: PFTF-50

Key Challenges, Trends, and Changes Transforming the Life Sciences Industry

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers.

This analysis explores the strategic imperatives shaping and transforming the life sciences industry. They are as follows: SaaS evolution provides adaptive intelligence for laboratories CDMOs augment competencies in new modalities, and digital transformation delivers end-to-end partnerships Expanding direct-to-consumer (DTC) genetic testing beyond ancestry testing to multi-pathogenic STIs Uncertainty about trade wars disrupts pharmaceutical supply chains Decentralized clinical trials (DCTs) boost efficiency for CGTs and rare disorders Next-generation sequencing (NGS) and liquid biopsy revolutionize oncology diagnostics Failed clinical trials and shifting market conditions setback biotech innovation ESG initiatives climb to the top of CEOs' strategic priorities Real-world insight (RWI) emerges as a strategic compass point to reimagine commercial strategies CRISPR technology advances biologics R&D

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
Top Transformations Impacting the Growth of the Life Sciences Industry
Key Industry Trends and Challenges

Top 10 Transformations Impacting Growth in the Life Sciences Industry, 2025

Transformation 1: SaaS Evolution Provides Adaptive Intelligence for Laboratories
Transformation 2: CDMOs Augment Competencies in New Modalities, and Digital Transformation Delivers End-to-End Partnerships
Transformation 3: Expanding Direct-to-Consumer (DTC) Genetic Testing Beyond Ancestry Testing to Multi-pathogenic STIs
Transformation 4: Uncertainty About Trade Wars Disrupts Pharmaceutical Supply Chains
Transformation 5: Decentralized Clinical Trials (DCTs) Boosting Efficiency for CGTs and Rare Disorders
Transformation 6: Next-generation Sequencing (NGS) and Liquid Biopsy Revolutionize Oncology Diagnostics
Transformation 7: Failed Clinical Trials and Shifting Market Conditions Setback Biotech Innovation
Transformation 8: ESG Initiatives Climb to the Top of CEOs' Strategic Priorities
Transformation 9: Real-world Insight (RWI) Emerges as a Strategic Compass Point to Reimagine Commercial Strategies
Transformation 10: CRISPR Technology Advances Biologics R&D
Frost & Sullivan Analytics Perspectives